Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

EuroIntervention 2015;10:1276-1279 published online ahead of print August 2014. DOI: 10.4244/EIJY14M08_11

Marije M. Löwik
Marije M. Löwik1, PhD; Ming Kai Lam1, MD; Hanim Sen1, MD; Kenneth Tandjung1, MD, PhD; K. Gert van Houwelingen1, MD; Frits H.A.F. de Man1, MD, PhD; Martin G. Stoel1, MD, PhD; J. (Hans) W. Louwerenburg1, MD; Gerard C.M. Linssen2, MD, PhD; Carine J.M. Doggen3, PhD; Clemens von Birgelen1,3*, MD, PhD
1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands; 2. Department of Cardiology, Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands; 3. Health Technology and Services Research, MIRA – Institute f

Aims: To assess three-year clinical outcome following randomised use of the second-generation Resolute zotarolimus-eluting stent (ZES) and the XIENCE V everolimus-eluting stent (EES). For

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

co-cr eesco-cr r-zescoronary revascularisationeverolimus-eluting stent(s)long-term outcomelong-term result(s)percutaneous coronary intervention(s)randomised studysecond-generation drug-eluting stent(s)stent(s)stent thrombosistwente trialzotarolimus-eluting stent(s)
Read next article
Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial

Latest news